Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,999404,half-life,In the plasma of rabbit and cat as well as man the decline of 3H-activity was biphasic after i.v. administration with a half-life of 15 hr in the rabbit 6 hr in cat and man for the slower phase.,Metabolism and pharmacokinetics of orciprenaline in various animal species and man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/999404/),h,15,11226,DB00816,Orciprenaline
,999404,volume of distribution,The pharmacokinetic analysis of the post-infusion data in man resulted in an open two-compartment model with a high volume of distribution (ca. 700 liters).,Metabolism and pharmacokinetics of orciprenaline in various animal species and man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/999404/),l,700,11227,DB00816,Orciprenaline
,999404,total clearance,The total clearance (1400 ml/min) was rather high.,Metabolism and pharmacokinetics of orciprenaline in various animal species and man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/999404/),[ml] / [min],1400,11228,DB00816,Orciprenaline
,999404,renal clearance,The renal clearance contributed to 10 per cent only.,Metabolism and pharmacokinetics of orciprenaline in various animal species and man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/999404/),%,10,11229,DB00816,Orciprenaline
,999404,amount of drug absorbed,"The amount of drug absorbed after oral administration amounted to 44%, the reduced biovailability of 10 per cent indicated a fist-pass effect.",Metabolism and pharmacokinetics of orciprenaline in various animal species and man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/999404/),%,44,11230,DB00816,Orciprenaline
,999404,biovailability,"The amount of drug absorbed after oral administration amounted to 44%, the reduced biovailability of 10 per cent indicated a fist-pass effect.",Metabolism and pharmacokinetics of orciprenaline in various animal species and man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/999404/),%,10,11231,DB00816,Orciprenaline
,1614958,terminal half-life,"The pharmacokinetics were best described by an open three-compartment model with a terminal half-life of 200 min (gamma = 0.23 +/- 0.08 L/hr), a volume of distribution at steady state of 1.9 +/- 0.8 L/kg, and a clearance of 0.86 +/- 0.32 L/hr/kg, with 14 and 9% absorbed after nasal and pulmonary administration, respectively.",Pharmacokinetic/dynamic correlation of pulmonary and cardiac effects of fenoterol in asthmatic patients after different routes of administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1614958/),min,200,28694,DB00816,Orciprenaline
,1614958,gamma,"The pharmacokinetics were best described by an open three-compartment model with a terminal half-life of 200 min (gamma = 0.23 +/- 0.08 L/hr), a volume of distribution at steady state of 1.9 +/- 0.8 L/kg, and a clearance of 0.86 +/- 0.32 L/hr/kg, with 14 and 9% absorbed after nasal and pulmonary administration, respectively.",Pharmacokinetic/dynamic correlation of pulmonary and cardiac effects of fenoterol in asthmatic patients after different routes of administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1614958/),[l] / [h],0.23,28695,DB00816,Orciprenaline
,1614958,volume of distribution at steady state,"The pharmacokinetics were best described by an open three-compartment model with a terminal half-life of 200 min (gamma = 0.23 +/- 0.08 L/hr), a volume of distribution at steady state of 1.9 +/- 0.8 L/kg, and a clearance of 0.86 +/- 0.32 L/hr/kg, with 14 and 9% absorbed after nasal and pulmonary administration, respectively.",Pharmacokinetic/dynamic correlation of pulmonary and cardiac effects of fenoterol in asthmatic patients after different routes of administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1614958/),[l] / [kg],1.9,28696,DB00816,Orciprenaline
,1614958,clearance,"The pharmacokinetics were best described by an open three-compartment model with a terminal half-life of 200 min (gamma = 0.23 +/- 0.08 L/hr), a volume of distribution at steady state of 1.9 +/- 0.8 L/kg, and a clearance of 0.86 +/- 0.32 L/hr/kg, with 14 and 9% absorbed after nasal and pulmonary administration, respectively.",Pharmacokinetic/dynamic correlation of pulmonary and cardiac effects of fenoterol in asthmatic patients after different routes of administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1614958/),[l] / [h·kg],0.86,28697,DB00816,Orciprenaline
,2991865,half-life,The long half-life previously reported in the literature (7 hours) is mainly the half-life of inactive fenoterol metabolites.,"Fenoterol: a beta2-adrenergic agonist for use in asthma. Pharmacology, pharmacokinetics, clinical efficacy and adverse effects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2991865/),h,7,66681,DB00816,Orciprenaline
,8276054,Clearance,"Clearance and mean residence time were found to be 1990 (1879/2220; Median, Q25/Q75) ml/min and 9.2 (8.0/14.0) min in the pregnant and 2126 (1915/2130) ml/min and 16.6 (16.5/32.1) min in the nonpregnant women, respectively.",Pharmacokinetics of fenoterol in pregnant and nonpregnant women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8276054/),[ml] / [min],1990,87967,DB00816,Orciprenaline
,8276054,Clearance,"Clearance and mean residence time were found to be 1990 (1879/2220; Median, Q25/Q75) ml/min and 9.2 (8.0/14.0) min in the pregnant and 2126 (1915/2130) ml/min and 16.6 (16.5/32.1) min in the nonpregnant women, respectively.",Pharmacokinetics of fenoterol in pregnant and nonpregnant women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8276054/),[ml] / [min],2126,87968,DB00816,Orciprenaline
,8276054,mean residence time,"Clearance and mean residence time were found to be 1990 (1879/2220; Median, Q25/Q75) ml/min and 9.2 (8.0/14.0) min in the pregnant and 2126 (1915/2130) ml/min and 16.6 (16.5/32.1) min in the nonpregnant women, respectively.",Pharmacokinetics of fenoterol in pregnant and nonpregnant women. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8276054/),min,9.2,87969,DB00816,Orciprenaline
,8276054,mean residence time,"Clearance and mean residence time were found to be 1990 (1879/2220; Median, Q25/Q75) ml/min and 9.2 (8.0/14.0) min in the pregnant and 2126 (1915/2130) ml/min and 16.6 (16.5/32.1) min in the nonpregnant women, respectively.",Pharmacokinetics of fenoterol in pregnant and nonpregnant women. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8276054/),min,16.6,87970,DB00816,Orciprenaline
,1303922,steady state concentration,Verapamil in a dose of 2 x 80 mg/day induced average steady state concentration in range of 40.6 +/- 7.8 ng/ml to 134.2 +/- 56.9 ng/ml and in a dose of 3 x 40 mg/day 28.9 +/- 5.1 ng/ml to 69.8 +/- 11.2 ng/ml.,[Pharmacokinetic investigations of verapamil used as a concomitant drug in treatment of premature labor]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1303922/),[ng] / [ml],40.6,88354,DB00816,Orciprenaline
,1303922,steady state concentration,Verapamil in a dose of 2 x 80 mg/day induced average steady state concentration in range of 40.6 +/- 7.8 ng/ml to 134.2 +/- 56.9 ng/ml and in a dose of 3 x 40 mg/day 28.9 +/- 5.1 ng/ml to 69.8 +/- 11.2 ng/ml.,[Pharmacokinetic investigations of verapamil used as a concomitant drug in treatment of premature labor]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1303922/),[ng] / [ml],134.2,88355,DB00816,Orciprenaline
,1303922,steady state concentration,Verapamil in a dose of 2 x 80 mg/day induced average steady state concentration in range of 40.6 +/- 7.8 ng/ml to 134.2 +/- 56.9 ng/ml and in a dose of 3 x 40 mg/day 28.9 +/- 5.1 ng/ml to 69.8 +/- 11.2 ng/ml.,[Pharmacokinetic investigations of verapamil used as a concomitant drug in treatment of premature labor]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1303922/),[ng] / [ml],28.9,88356,DB00816,Orciprenaline
,1303922,steady state concentration,Verapamil in a dose of 2 x 80 mg/day induced average steady state concentration in range of 40.6 +/- 7.8 ng/ml to 134.2 +/- 56.9 ng/ml and in a dose of 3 x 40 mg/day 28.9 +/- 5.1 ng/ml to 69.8 +/- 11.2 ng/ml.,[Pharmacokinetic investigations of verapamil used as a concomitant drug in treatment of premature labor]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1303922/),[ng] / [ml],69.8,88357,DB00816,Orciprenaline
,12959305,maximum increase,"3. Cumulative doses of fenoterol DPC and MDI (0.2, 0.6, 1.4, 3.0, 6.2 mg), investigated in 12 subjects, produced a comparable bronchodilatation (mean maximum increase in FEV1 was 0.53 +/- 0.06/0.52 +/- 0.081 for DPC/MDI) and a similar, dose-dependent rise in heart rate (35 +/- 3.81/41 +/- 2.25 beats min(-1)).","Studies on the bronchodilator, tremorogenic, cardiovascular and hypokalaemic effects of fenoterol dry powder in asthma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959305/),,0.53,102980,DB00816,Orciprenaline
,12959305,maximum increase,"3. Cumulative doses of fenoterol DPC and MDI (0.2, 0.6, 1.4, 3.0, 6.2 mg), investigated in 12 subjects, produced a comparable bronchodilatation (mean maximum increase in FEV1 was 0.53 +/- 0.06/0.52 +/- 0.081 for DPC/MDI) and a similar, dose-dependent rise in heart rate (35 +/- 3.81/41 +/- 2.25 beats min(-1)).","Studies on the bronchodilator, tremorogenic, cardiovascular and hypokalaemic effects of fenoterol dry powder in asthma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959305/),,0.52,102981,DB00816,Orciprenaline
,12959305,heart rate,"3. Cumulative doses of fenoterol DPC and MDI (0.2, 0.6, 1.4, 3.0, 6.2 mg), investigated in 12 subjects, produced a comparable bronchodilatation (mean maximum increase in FEV1 was 0.53 +/- 0.06/0.52 +/- 0.081 for DPC/MDI) and a similar, dose-dependent rise in heart rate (35 +/- 3.81/41 +/- 2.25 beats min(-1)).","Studies on the bronchodilator, tremorogenic, cardiovascular and hypokalaemic effects of fenoterol dry powder in asthma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959305/),[beats] / [min],35,102982,DB00816,Orciprenaline
,12959305,heart rate,"3. Cumulative doses of fenoterol DPC and MDI (0.2, 0.6, 1.4, 3.0, 6.2 mg), investigated in 12 subjects, produced a comparable bronchodilatation (mean maximum increase in FEV1 was 0.53 +/- 0.06/0.52 +/- 0.081 for DPC/MDI) and a similar, dose-dependent rise in heart rate (35 +/- 3.81/41 +/- 2.25 beats min(-1)).","Studies on the bronchodilator, tremorogenic, cardiovascular and hypokalaemic effects of fenoterol dry powder in asthma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959305/),[beats] / [min],41,102983,DB00816,Orciprenaline
,12959305,maximum changes,The mean maximum changes were 51.58 +/- 6.41/95.83 +/- 6.75 cm s(-2) for tremor and -0.68 +/- 0.09/-0.96 +/- 0.10 mmol l(-1) for potassium.,"Studies on the bronchodilator, tremorogenic, cardiovascular and hypokalaemic effects of fenoterol dry powder in asthma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959305/),[cm] / [(s)^2],51.58,102984,DB00816,Orciprenaline
,12959305,maximum changes,The mean maximum changes were 51.58 +/- 6.41/95.83 +/- 6.75 cm s(-2) for tremor and -0.68 +/- 0.09/-0.96 +/- 0.10 mmol l(-1) for potassium.,"Studies on the bronchodilator, tremorogenic, cardiovascular and hypokalaemic effects of fenoterol dry powder in asthma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959305/),[cm] / [(s)^2],95.83,102985,DB00816,Orciprenaline
,12959305,maximum changes,The mean maximum changes were 51.58 +/- 6.41/95.83 +/- 6.75 cm s(-2) for tremor and -0.68 +/- 0.09/-0.96 +/- 0.10 mmol l(-1) for potassium.,"Studies on the bronchodilator, tremorogenic, cardiovascular and hypokalaemic effects of fenoterol dry powder in asthma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959305/),[mM] / [l],-,102986,DB00816,Orciprenaline
,12959305,maximum changes,The mean maximum changes were 51.58 +/- 6.41/95.83 +/- 6.75 cm s(-2) for tremor and -0.68 +/- 0.09/-0.96 +/- 0.10 mmol l(-1) for potassium.,"Studies on the bronchodilator, tremorogenic, cardiovascular and hypokalaemic effects of fenoterol dry powder in asthma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959305/),[mM] / [l],0.68,102987,DB00816,Orciprenaline
,3403868,FEV1,"Mean values for FEV1 (1.2 versus 1.3 L), FEV1/FVC (77% versus 79%), and reduction in acute metaproterenol use (24% versus 43%) in children receiving theophylline suspension and aminophylline solution revealed no differences between products.",Clinical and pharmacokinetic evaluation of a sustained-release liquid theophylline preparation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3403868/),l,1.2,104304,DB00816,Orciprenaline
,3403868,FEV1,"Mean values for FEV1 (1.2 versus 1.3 L), FEV1/FVC (77% versus 79%), and reduction in acute metaproterenol use (24% versus 43%) in children receiving theophylline suspension and aminophylline solution revealed no differences between products.",Clinical and pharmacokinetic evaluation of a sustained-release liquid theophylline preparation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3403868/),l,1.3,104305,DB00816,Orciprenaline
,3403868,peak theophylline blood level,"The suspension demonstrated a lower peak theophylline blood level at a later time (11.6 micrograms/ml at 3 1/2 hours), compared to the solution (14.6 micrograms/ml at 1 1/2 hours; p less than or equal to 0.01).",Clinical and pharmacokinetic evaluation of a sustained-release liquid theophylline preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3403868/),[μg] / [ml],11.6,104306,DB00816,Orciprenaline
,3403868,peak theophylline blood level,"The suspension demonstrated a lower peak theophylline blood level at a later time (11.6 micrograms/ml at 3 1/2 hours), compared to the solution (14.6 micrograms/ml at 1 1/2 hours; p less than or equal to 0.01).",Clinical and pharmacokinetic evaluation of a sustained-release liquid theophylline preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3403868/),[μg] / [ml],14.6,104307,DB00816,Orciprenaline
,3403868,Relative bioavailability,Relative bioavailability of theophylline suspension was 89% of that for the solution.,Clinical and pharmacokinetic evaluation of a sustained-release liquid theophylline preparation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3403868/),%,89,104308,DB00816,Orciprenaline
,20039779,net exposure,"The oral administration revealed that the net exposure of (R,R)-MFen was about three-fold higher than that of (R,R)-Fen (7.2 versus 2.3 min x nmol ml(-1)), while intravenous administration proved that the clearance was significantly reduced, 48 versus 146 ml min(-1) kg(-1), the T(1/2) was significantly longer, 152.9 versus 108.9 min, and the area under the curve (AUC) was significantly increased, 300 versus 119 min x nmol ml(-1).","Pharmacokinetics and metabolism of (R,R)-methoxyfenoterol in rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20039779/),[min·nM] / [ml],7.2,110862,DB00816,Orciprenaline
,20039779,net exposure,"The oral administration revealed that the net exposure of (R,R)-MFen was about three-fold higher than that of (R,R)-Fen (7.2 versus 2.3 min x nmol ml(-1)), while intravenous administration proved that the clearance was significantly reduced, 48 versus 146 ml min(-1) kg(-1), the T(1/2) was significantly longer, 152.9 versus 108.9 min, and the area under the curve (AUC) was significantly increased, 300 versus 119 min x nmol ml(-1).","Pharmacokinetics and metabolism of (R,R)-methoxyfenoterol in rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20039779/),[min·nM] / [ml],2.3,110863,DB00816,Orciprenaline
,20039779,clearance,"The oral administration revealed that the net exposure of (R,R)-MFen was about three-fold higher than that of (R,R)-Fen (7.2 versus 2.3 min x nmol ml(-1)), while intravenous administration proved that the clearance was significantly reduced, 48 versus 146 ml min(-1) kg(-1), the T(1/2) was significantly longer, 152.9 versus 108.9 min, and the area under the curve (AUC) was significantly increased, 300 versus 119 min x nmol ml(-1).","Pharmacokinetics and metabolism of (R,R)-methoxyfenoterol in rat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20039779/),[ml] / [kg·min],48,110864,DB00816,Orciprenaline
,20039779,clearance,"The oral administration revealed that the net exposure of (R,R)-MFen was about three-fold higher than that of (R,R)-Fen (7.2 versus 2.3 min x nmol ml(-1)), while intravenous administration proved that the clearance was significantly reduced, 48 versus 146 ml min(-1) kg(-1), the T(1/2) was significantly longer, 152.9 versus 108.9 min, and the area under the curve (AUC) was significantly increased, 300 versus 119 min x nmol ml(-1).","Pharmacokinetics and metabolism of (R,R)-methoxyfenoterol in rat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20039779/),[ml] / [kg·min],146,110865,DB00816,Orciprenaline
,20039779,T(1/2),"The oral administration revealed that the net exposure of (R,R)-MFen was about three-fold higher than that of (R,R)-Fen (7.2 versus 2.3 min x nmol ml(-1)), while intravenous administration proved that the clearance was significantly reduced, 48 versus 146 ml min(-1) kg(-1), the T(1/2) was significantly longer, 152.9 versus 108.9 min, and the area under the curve (AUC) was significantly increased, 300 versus 119 min x nmol ml(-1).","Pharmacokinetics and metabolism of (R,R)-methoxyfenoterol in rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20039779/),min,152.9,110866,DB00816,Orciprenaline
,20039779,T(1/2),"The oral administration revealed that the net exposure of (R,R)-MFen was about three-fold higher than that of (R,R)-Fen (7.2 versus 2.3 min x nmol ml(-1)), while intravenous administration proved that the clearance was significantly reduced, 48 versus 146 ml min(-1) kg(-1), the T(1/2) was significantly longer, 152.9 versus 108.9 min, and the area under the curve (AUC) was significantly increased, 300 versus 119 min x nmol ml(-1).","Pharmacokinetics and metabolism of (R,R)-methoxyfenoterol in rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20039779/),min,108.9,110867,DB00816,Orciprenaline
,20039779,area under the curve (AUC),"The oral administration revealed that the net exposure of (R,R)-MFen was about three-fold higher than that of (R,R)-Fen (7.2 versus 2.3 min x nmol ml(-1)), while intravenous administration proved that the clearance was significantly reduced, 48 versus 146 ml min(-1) kg(-1), the T(1/2) was significantly longer, 152.9 versus 108.9 min, and the area under the curve (AUC) was significantly increased, 300 versus 119 min x nmol ml(-1).","Pharmacokinetics and metabolism of (R,R)-methoxyfenoterol in rat. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20039779/),[min·nM] / [ml],300,110868,DB00816,Orciprenaline
,20039779,area under the curve (AUC),"The oral administration revealed that the net exposure of (R,R)-MFen was about three-fold higher than that of (R,R)-Fen (7.2 versus 2.3 min x nmol ml(-1)), while intravenous administration proved that the clearance was significantly reduced, 48 versus 146 ml min(-1) kg(-1), the T(1/2) was significantly longer, 152.9 versus 108.9 min, and the area under the curve (AUC) was significantly increased, 300 versus 119 min x nmol ml(-1).","Pharmacokinetics and metabolism of (R,R)-methoxyfenoterol in rat. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20039779/),[min·nM] / [ml],119,110869,DB00816,Orciprenaline
,2863112,extraction ratios,"Presystemic intestinal (EGpre) and liver (EH) extraction ratios, EGpre = 0.93 +/- 0.01, EH = 0.67 +/- 0.04, were calculated from AUC values after intraduodenal, intraportal, and iv administration.",Presystemic and systemic intestinal metabolism of fenoterol in the conscious rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863112/),,0.93,154433,DB00816,Orciprenaline
,2863112,extraction ratios,"Presystemic intestinal (EGpre) and liver (EH) extraction ratios, EGpre = 0.93 +/- 0.01, EH = 0.67 +/- 0.04, were calculated from AUC values after intraduodenal, intraportal, and iv administration.",Presystemic and systemic intestinal metabolism of fenoterol in the conscious rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863112/),,0.67,154434,DB00816,Orciprenaline
,2863112,Total systemic availability,Total systemic availability after intraduodenal administration ranged from 0.8 (10 mg/kg) to 1.2% (40 mg/kg).,Presystemic and systemic intestinal metabolism of fenoterol in the conscious rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863112/),%,0.8,154435,DB00816,Orciprenaline
,2863112,Total systemic availability,Total systemic availability after intraduodenal administration ranged from 0.8 (10 mg/kg) to 1.2% (40 mg/kg).,Presystemic and systemic intestinal metabolism of fenoterol in the conscious rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863112/),%,1.2,154436,DB00816,Orciprenaline
,2863112,intestinal extraction ratio,"During iv infusion (30 micrograms fenoterol/min X kg), an intestinal extraction ratio of EG = 0.26 was observed.",Presystemic and systemic intestinal metabolism of fenoterol in the conscious rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863112/),,0.26,154437,DB00816,Orciprenaline
,2863112,systemic clearance (Cl,Doubling of the dose resulted in an increase of systemic clearance (Cl = 53.8 +/- 2.7 and 74.4 +/- 1.8 ml/min X kg) and distribution volume (Vss = 0.95 +/- 0.13 and 1.21 +/- 0.11 liters/kg); the mean residence time (17.9 +/- 2.4 and 16.3 +/- 1.4 min) and terminal half-life (45.8 +/- 5.5 and 46.8 +/- 2.8 min) were not changed.,Presystemic and systemic intestinal metabolism of fenoterol in the conscious rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863112/),[ml] / [kg·min],53.8,154438,DB00816,Orciprenaline
,2863112,systemic clearance (Cl,Doubling of the dose resulted in an increase of systemic clearance (Cl = 53.8 +/- 2.7 and 74.4 +/- 1.8 ml/min X kg) and distribution volume (Vss = 0.95 +/- 0.13 and 1.21 +/- 0.11 liters/kg); the mean residence time (17.9 +/- 2.4 and 16.3 +/- 1.4 min) and terminal half-life (45.8 +/- 5.5 and 46.8 +/- 2.8 min) were not changed.,Presystemic and systemic intestinal metabolism of fenoterol in the conscious rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863112/),[ml] / [kg·min],74.4,154439,DB00816,Orciprenaline
,2863112,distribution volume (Vss,Doubling of the dose resulted in an increase of systemic clearance (Cl = 53.8 +/- 2.7 and 74.4 +/- 1.8 ml/min X kg) and distribution volume (Vss = 0.95 +/- 0.13 and 1.21 +/- 0.11 liters/kg); the mean residence time (17.9 +/- 2.4 and 16.3 +/- 1.4 min) and terminal half-life (45.8 +/- 5.5 and 46.8 +/- 2.8 min) were not changed.,Presystemic and systemic intestinal metabolism of fenoterol in the conscious rat. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863112/),[l] / [kg],0.95,154440,DB00816,Orciprenaline
,2863112,distribution volume (Vss,Doubling of the dose resulted in an increase of systemic clearance (Cl = 53.8 +/- 2.7 and 74.4 +/- 1.8 ml/min X kg) and distribution volume (Vss = 0.95 +/- 0.13 and 1.21 +/- 0.11 liters/kg); the mean residence time (17.9 +/- 2.4 and 16.3 +/- 1.4 min) and terminal half-life (45.8 +/- 5.5 and 46.8 +/- 2.8 min) were not changed.,Presystemic and systemic intestinal metabolism of fenoterol in the conscious rat. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863112/),[l] / [kg],1.21,154441,DB00816,Orciprenaline
,2863112,mean residence time,Doubling of the dose resulted in an increase of systemic clearance (Cl = 53.8 +/- 2.7 and 74.4 +/- 1.8 ml/min X kg) and distribution volume (Vss = 0.95 +/- 0.13 and 1.21 +/- 0.11 liters/kg); the mean residence time (17.9 +/- 2.4 and 16.3 +/- 1.4 min) and terminal half-life (45.8 +/- 5.5 and 46.8 +/- 2.8 min) were not changed.,Presystemic and systemic intestinal metabolism of fenoterol in the conscious rat. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863112/),min,17.9,154442,DB00816,Orciprenaline
,2863112,mean residence time,Doubling of the dose resulted in an increase of systemic clearance (Cl = 53.8 +/- 2.7 and 74.4 +/- 1.8 ml/min X kg) and distribution volume (Vss = 0.95 +/- 0.13 and 1.21 +/- 0.11 liters/kg); the mean residence time (17.9 +/- 2.4 and 16.3 +/- 1.4 min) and terminal half-life (45.8 +/- 5.5 and 46.8 +/- 2.8 min) were not changed.,Presystemic and systemic intestinal metabolism of fenoterol in the conscious rat. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863112/),min,16.3,154443,DB00816,Orciprenaline
,2863112,terminal half-life,Doubling of the dose resulted in an increase of systemic clearance (Cl = 53.8 +/- 2.7 and 74.4 +/- 1.8 ml/min X kg) and distribution volume (Vss = 0.95 +/- 0.13 and 1.21 +/- 0.11 liters/kg); the mean residence time (17.9 +/- 2.4 and 16.3 +/- 1.4 min) and terminal half-life (45.8 +/- 5.5 and 46.8 +/- 2.8 min) were not changed.,Presystemic and systemic intestinal metabolism of fenoterol in the conscious rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863112/),min,45.8,154444,DB00816,Orciprenaline
,2863112,terminal half-life,Doubling of the dose resulted in an increase of systemic clearance (Cl = 53.8 +/- 2.7 and 74.4 +/- 1.8 ml/min X kg) and distribution volume (Vss = 0.95 +/- 0.13 and 1.21 +/- 0.11 liters/kg); the mean residence time (17.9 +/- 2.4 and 16.3 +/- 1.4 min) and terminal half-life (45.8 +/- 5.5 and 46.8 +/- 2.8 min) were not changed.,Presystemic and systemic intestinal metabolism of fenoterol in the conscious rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863112/),min,46.8,154445,DB00816,Orciprenaline
,3935852,elimination half-life,"The mean values during control, propranolol, and metoprolol trials of DNG elimination half-life were: 1.35, 1.10, and 1.09 h; total area under the curve: 42, 38, and 42 ng/ml X h; oral clearance: 6.6, 7.2, and 6.4 liters/min.","Kinetics of 1,2-dinitroglycerin following sustained release nitroglycerin: influence of propranolol and metoprolol. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3935852/),h,1.35,158315,DB00816,Orciprenaline
,3935852,elimination half-life,"The mean values during control, propranolol, and metoprolol trials of DNG elimination half-life were: 1.35, 1.10, and 1.09 h; total area under the curve: 42, 38, and 42 ng/ml X h; oral clearance: 6.6, 7.2, and 6.4 liters/min.","Kinetics of 1,2-dinitroglycerin following sustained release nitroglycerin: influence of propranolol and metoprolol. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3935852/),h,1.10,158316,DB00816,Orciprenaline
,3935852,elimination half-life,"The mean values during control, propranolol, and metoprolol trials of DNG elimination half-life were: 1.35, 1.10, and 1.09 h; total area under the curve: 42, 38, and 42 ng/ml X h; oral clearance: 6.6, 7.2, and 6.4 liters/min.","Kinetics of 1,2-dinitroglycerin following sustained release nitroglycerin: influence of propranolol and metoprolol. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3935852/),h,1.09,158317,DB00816,Orciprenaline
,3935852,total area under the curve,"The mean values during control, propranolol, and metoprolol trials of DNG elimination half-life were: 1.35, 1.10, and 1.09 h; total area under the curve: 42, 38, and 42 ng/ml X h; oral clearance: 6.6, 7.2, and 6.4 liters/min.","Kinetics of 1,2-dinitroglycerin following sustained release nitroglycerin: influence of propranolol and metoprolol. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3935852/),[ng] / [h·ml],42,158318,DB00816,Orciprenaline
,3935852,total area under the curve,"The mean values during control, propranolol, and metoprolol trials of DNG elimination half-life were: 1.35, 1.10, and 1.09 h; total area under the curve: 42, 38, and 42 ng/ml X h; oral clearance: 6.6, 7.2, and 6.4 liters/min.","Kinetics of 1,2-dinitroglycerin following sustained release nitroglycerin: influence of propranolol and metoprolol. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3935852/),[ng] / [h·ml],38,158319,DB00816,Orciprenaline
,3935852,oral clearance,"The mean values during control, propranolol, and metoprolol trials of DNG elimination half-life were: 1.35, 1.10, and 1.09 h; total area under the curve: 42, 38, and 42 ng/ml X h; oral clearance: 6.6, 7.2, and 6.4 liters/min.","Kinetics of 1,2-dinitroglycerin following sustained release nitroglycerin: influence of propranolol and metoprolol. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3935852/),[l] / [min],6.6,158320,DB00816,Orciprenaline
,3935852,oral clearance,"The mean values during control, propranolol, and metoprolol trials of DNG elimination half-life were: 1.35, 1.10, and 1.09 h; total area under the curve: 42, 38, and 42 ng/ml X h; oral clearance: 6.6, 7.2, and 6.4 liters/min.","Kinetics of 1,2-dinitroglycerin following sustained release nitroglycerin: influence of propranolol and metoprolol. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3935852/),[l] / [min],7.2,158321,DB00816,Orciprenaline
,3935852,oral clearance,"The mean values during control, propranolol, and metoprolol trials of DNG elimination half-life were: 1.35, 1.10, and 1.09 h; total area under the curve: 42, 38, and 42 ng/ml X h; oral clearance: 6.6, 7.2, and 6.4 liters/min.","Kinetics of 1,2-dinitroglycerin following sustained release nitroglycerin: influence of propranolol and metoprolol. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3935852/),[l] / [min],6.4,158322,DB00816,Orciprenaline
,6140141,(M-H)- m/z,Negative and positive ion fast atom bombardment/mass spectrometry showed the metabolite to have a (M-H)- m/z of 290 and a (M + H)+ m/z ion of 292.,Isolation and characterization of metaproterenol-3-O-sulfate: a conjugate of metaproterenol in human urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6140141/),,290,158699,DB00816,Orciprenaline
,6140141,biological half-life,The majority of the dose was excreted over the first 12 hr with a biological half-life of 5-6 hr followed by a slower excretion phase with a half-life of 20 hr.,Isolation and characterization of metaproterenol-3-O-sulfate: a conjugate of metaproterenol in human urine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6140141/),h,5-6,158700,DB00816,Orciprenaline
,6140141,half-life,The majority of the dose was excreted over the first 12 hr with a biological half-life of 5-6 hr followed by a slower excretion phase with a half-life of 20 hr.,Isolation and characterization of metaproterenol-3-O-sulfate: a conjugate of metaproterenol in human urine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6140141/),h,20,158701,DB00816,Orciprenaline
,7191273,half-life,"After oral administration, 3H-fenoterol was absorbed quickly, reaching a maximum concentration level within 0.5 h after administration, and decreased thereafter with a half-life of about 2 h.","Studies on the absorption, distribution, metabolism and excretion of 1-(3,5-dihydroxyphenyl)-1-hydroxy-2-[(4-hydroxyphenyl)isopropylamino]-ethane hydrobromide (Th 1165 a, fenoterol hydrobromide) in mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7191273/),h,2,167846,DB00816,Orciprenaline
,7191273,rates of excretion,"The rates of excretion in urine and in feces in 72 h were ca. 81% and 16%, respectively, with i.v. administration and ca. 45% and 45%, respectively, with oral administration.","Studies on the absorption, distribution, metabolism and excretion of 1-(3,5-dihydroxyphenyl)-1-hydroxy-2-[(4-hydroxyphenyl)isopropylamino]-ethane hydrobromide (Th 1165 a, fenoterol hydrobromide) in mice. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7191273/),%,81,167847,DB00816,Orciprenaline
,7191273,rates of excretion,"The rates of excretion in urine and in feces in 72 h were ca. 81% and 16%, respectively, with i.v. administration and ca. 45% and 45%, respectively, with oral administration.","Studies on the absorption, distribution, metabolism and excretion of 1-(3,5-dihydroxyphenyl)-1-hydroxy-2-[(4-hydroxyphenyl)isopropylamino]-ethane hydrobromide (Th 1165 a, fenoterol hydrobromide) in mice. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7191273/),%,16,167848,DB00816,Orciprenaline
,7191273,rates of excretion,"The rates of excretion in urine and in feces in 72 h were ca. 81% and 16%, respectively, with i.v. administration and ca. 45% and 45%, respectively, with oral administration.","Studies on the absorption, distribution, metabolism and excretion of 1-(3,5-dihydroxyphenyl)-1-hydroxy-2-[(4-hydroxyphenyl)isopropylamino]-ethane hydrobromide (Th 1165 a, fenoterol hydrobromide) in mice. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7191273/),%,45,167849,DB00816,Orciprenaline
,7191273,binding rate,"As a result, the binding rate with serum protein was 3--5%.","Studies on the absorption, distribution, metabolism and excretion of 1-(3,5-dihydroxyphenyl)-1-hydroxy-2-[(4-hydroxyphenyl)isopropylamino]-ethane hydrobromide (Th 1165 a, fenoterol hydrobromide) in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7191273/),%,3,167850,DB00816,Orciprenaline
,7710446,steady state concentration (css),"From a steady state concentration (css) of 2242 +/- 391 pg/ml (x +/- S.E.), a non-linear two-phased plasma elimination was seen with half-lives t1/2 of 11.40 min and 4.87 h.",Pharmacokinetics of fenoterol in pregnant women. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7710446/),[pg] / [ml],2242,195528,DB00816,Orciprenaline
,7710446,half-lives t1/2,"From a steady state concentration (css) of 2242 +/- 391 pg/ml (x +/- S.E.), a non-linear two-phased plasma elimination was seen with half-lives t1/2 of 11.40 min and 4.87 h.",Pharmacokinetics of fenoterol in pregnant women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7710446/),min,11.40,195529,DB00816,Orciprenaline
,7710446,half-lives t1/2,"From a steady state concentration (css) of 2242 +/- 391 pg/ml (x +/- S.E.), a non-linear two-phased plasma elimination was seen with half-lives t1/2 of 11.40 min and 4.87 h.",Pharmacokinetics of fenoterol in pregnant women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7710446/),h,4.87,195530,DB00816,Orciprenaline
,7710446,area under the plasma concentration-time curve (AUC0-12h),The area under the plasma concentration-time curve (AUC0-12h) was 6.27 ng/ml x h.,Pharmacokinetics of fenoterol in pregnant women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7710446/),[ng] / [h·ml],6.27,195531,DB00816,Orciprenaline
,7710446,total clearance (Cltot),The total clearance (Cltot) was 114.8 l/h.,Pharmacokinetics of fenoterol in pregnant women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7710446/),[l] / [h],114.8,195532,DB00816,Orciprenaline
,3783458,bioavailability,"The bioavailability of the tablet formulation relative to that of the oral solution was 92 +/- 9%, with excellent power at the 5% significance level.","Relative bioavailability of metaproterenol in humans utilizing a single dose, stable isotope approach. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3783458/),%,92,202783,DB00816,Orciprenaline
,3783458,peak plasma concentrations,"Following oral administration, metaproterenol showed peak plasma concentrations of 2.2 to 13 ng/mL at 0.75 to 3.0 h, with a terminal harmonic mean half-life of 2.1 h over the plasma concentration range studied.","Relative bioavailability of metaproterenol in humans utilizing a single dose, stable isotope approach. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3783458/),[ng] / [ml],2.2 to 13,202784,DB00816,Orciprenaline
,3783458,terminal harmonic mean half-life,"Following oral administration, metaproterenol showed peak plasma concentrations of 2.2 to 13 ng/mL at 0.75 to 3.0 h, with a terminal harmonic mean half-life of 2.1 h over the plasma concentration range studied.","Relative bioavailability of metaproterenol in humans utilizing a single dose, stable isotope approach. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3783458/),h,2.1,202785,DB00816,Orciprenaline
,3783458,renal clearance,The renal clearance of 133-158 mL/min for metaproterenol slightly exceeds the glomerular filtration rate in humans.,"Relative bioavailability of metaproterenol in humans utilizing a single dose, stable isotope approach. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3783458/),[ml] / [min],133-158,202786,DB00816,Orciprenaline
,1493852,total clearance,"The total clearance of fenoterol increased with dose (1299 ml.min-1 at 0.5 microgram.min-1, 1483 ml.min-1 at 1.0 micrograms.min-1, and 1924 ml.min-1 at 2.0 micrograms.min-1), as did the apparent volume of distribution (from 49 l at the lowest to 85 l at the highest dose).",The pharmacokinetics of the beta 2-adrenoceptor agonist fenoterol in healthy women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1493852/),[ml] / [min],1299,204592,DB00816,Orciprenaline
,1493852,total clearance,"The total clearance of fenoterol increased with dose (1299 ml.min-1 at 0.5 microgram.min-1, 1483 ml.min-1 at 1.0 micrograms.min-1, and 1924 ml.min-1 at 2.0 micrograms.min-1), as did the apparent volume of distribution (from 49 l at the lowest to 85 l at the highest dose).",The pharmacokinetics of the beta 2-adrenoceptor agonist fenoterol in healthy women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1493852/),[ml] / [min],1483,204593,DB00816,Orciprenaline
,1493852,total clearance,"The total clearance of fenoterol increased with dose (1299 ml.min-1 at 0.5 microgram.min-1, 1483 ml.min-1 at 1.0 micrograms.min-1, and 1924 ml.min-1 at 2.0 micrograms.min-1), as did the apparent volume of distribution (from 49 l at the lowest to 85 l at the highest dose).",The pharmacokinetics of the beta 2-adrenoceptor agonist fenoterol in healthy women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1493852/),[ml] / [min],1924,204594,DB00816,Orciprenaline
,1493852,apparent volume of distribution,"The total clearance of fenoterol increased with dose (1299 ml.min-1 at 0.5 microgram.min-1, 1483 ml.min-1 at 1.0 micrograms.min-1, and 1924 ml.min-1 at 2.0 micrograms.min-1), as did the apparent volume of distribution (from 49 l at the lowest to 85 l at the highest dose).",The pharmacokinetics of the beta 2-adrenoceptor agonist fenoterol in healthy women. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1493852/),l,49,204595,DB00816,Orciprenaline
,1493852,apparent volume of distribution,"The total clearance of fenoterol increased with dose (1299 ml.min-1 at 0.5 microgram.min-1, 1483 ml.min-1 at 1.0 micrograms.min-1, and 1924 ml.min-1 at 2.0 micrograms.min-1), as did the apparent volume of distribution (from 49 l at the lowest to 85 l at the highest dose).",The pharmacokinetics of the beta 2-adrenoceptor agonist fenoterol in healthy women. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1493852/),l,85,204596,DB00816,Orciprenaline
,1493852,t1/2.lambda 1,"In contrast, the apparent half-lives were not dose-dependent, with t1/2.lambda 1 4.8 min and t1/2.lambda z 52 min.",The pharmacokinetics of the beta 2-adrenoceptor agonist fenoterol in healthy women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1493852/),min,4.8,204597,DB00816,Orciprenaline
,1493852,t1/2.lambda z,"In contrast, the apparent half-lives were not dose-dependent, with t1/2.lambda 1 4.8 min and t1/2.lambda z 52 min.",The pharmacokinetics of the beta 2-adrenoceptor agonist fenoterol in healthy women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1493852/),min,52,204598,DB00816,Orciprenaline
,3395671,plasma level maxima,"After one tablet, plasma level maxima (of plateau-type) were 5-6 ng ml-1 and 2-3 ng ml-1 in two subjects, respectively.","Plasma levels, heart rate, and blood pressure after intravenous, oral, and aerosol administration of reproterol in man. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3395671/),[ng] / [ml],5-6,209285,DB00816,Orciprenaline
,3395671,plasma level maxima,"After one tablet, plasma level maxima (of plateau-type) were 5-6 ng ml-1 and 2-3 ng ml-1 in two subjects, respectively.","Plasma levels, heart rate, and blood pressure after intravenous, oral, and aerosol administration of reproterol in man. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3395671/),[ng] / [ml],2-3,209286,DB00816,Orciprenaline
,3395671,plateau level maxima,"After two tablets, plateau level maxima around 18 ng ml-1 and 9 ng ml-1 were found, respectively.","Plasma levels, heart rate, and blood pressure after intravenous, oral, and aerosol administration of reproterol in man. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3395671/),[ng] / [ml],18,209287,DB00816,Orciprenaline
,3395671,plateau level maxima,"After two tablets, plateau level maxima around 18 ng ml-1 and 9 ng ml-1 were found, respectively.","Plasma levels, heart rate, and blood pressure after intravenous, oral, and aerosol administration of reproterol in man. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3395671/),[ng] / [ml],9,209288,DB00816,Orciprenaline
,6434219,elimination t1/2,"Propranolol prolonged diazepam elimination t1/2 (58 and 49 hr), reduced its clearance (0.20 and 0.24 ml/min/kg), and increased the 168-hr AUC for desmethyldiazepam, the major metabolite of diazepam (5.63 and 4.81 micrograms/ml . hr).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),h,58,222575,DB00816,Orciprenaline
,6434219,elimination t1/2,"Propranolol prolonged diazepam elimination t1/2 (58 and 49 hr), reduced its clearance (0.20 and 0.24 ml/min/kg), and increased the 168-hr AUC for desmethyldiazepam, the major metabolite of diazepam (5.63 and 4.81 micrograms/ml . hr).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),h,49,222576,DB00816,Orciprenaline
,6434219,clearance,"Propranolol prolonged diazepam elimination t1/2 (58 and 49 hr), reduced its clearance (0.20 and 0.24 ml/min/kg), and increased the 168-hr AUC for desmethyldiazepam, the major metabolite of diazepam (5.63 and 4.81 micrograms/ml . hr).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),[ml] / [kg·min],0.20,222577,DB00816,Orciprenaline
,6434219,clearance,"Propranolol prolonged diazepam elimination t1/2 (58 and 49 hr), reduced its clearance (0.20 and 0.24 ml/min/kg), and increased the 168-hr AUC for desmethyldiazepam, the major metabolite of diazepam (5.63 and 4.81 micrograms/ml . hr).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),[ml] / [kg·min],0.24,222578,DB00816,Orciprenaline
,6434219,clearance,"Propranolol prolonged diazepam elimination t1/2 (58 and 49 hr), reduced its clearance (0.20 and 0.24 ml/min/kg), and increased the 168-hr AUC for desmethyldiazepam, the major metabolite of diazepam (5.63 and 4.81 micrograms/ml . hr).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),,168,222579,DB00816,Orciprenaline
,6434219,AUC,"Propranolol prolonged diazepam elimination t1/2 (58 and 49 hr), reduced its clearance (0.20 and 0.24 ml/min/kg), and increased the 168-hr AUC for desmethyldiazepam, the major metabolite of diazepam (5.63 and 4.81 micrograms/ml . hr).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),,168,222580,DB00816,Orciprenaline
,6434219,AUC,"Propranolol prolonged diazepam elimination t1/2 (58 and 49 hr), reduced its clearance (0.20 and 0.24 ml/min/kg), and increased the 168-hr AUC for desmethyldiazepam, the major metabolite of diazepam (5.63 and 4.81 micrograms/ml . hr).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),[μg] / [h·ml],5.63,222581,DB00816,Orciprenaline
,6434219,AUC,"Propranolol prolonged diazepam elimination t1/2 (58 and 49 hr), reduced its clearance (0.20 and 0.24 ml/min/kg), and increased the 168-hr AUC for desmethyldiazepam, the major metabolite of diazepam (5.63 and 4.81 micrograms/ml . hr).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),[μg] / [h·ml],4.81,222582,DB00816,Orciprenaline
,6434219,t1/2,"Propranolol had no significant effect on lorazepam t1/2 (13.2 and 12.7 hr) or clearance (1.33 and 1.36 ml/min/kg), nor on alprazolam t1/2 (15.9 and 18.5 hr) or clearance (1.1 and 0.8 ml/min/kg).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),h,13.2,222583,DB00816,Orciprenaline
,6434219,t1/2,"Propranolol had no significant effect on lorazepam t1/2 (13.2 and 12.7 hr) or clearance (1.33 and 1.36 ml/min/kg), nor on alprazolam t1/2 (15.9 and 18.5 hr) or clearance (1.1 and 0.8 ml/min/kg).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),h,12.7,222584,DB00816,Orciprenaline
,6434219,clearance,"Propranolol had no significant effect on lorazepam t1/2 (13.2 and 12.7 hr) or clearance (1.33 and 1.36 ml/min/kg), nor on alprazolam t1/2 (15.9 and 18.5 hr) or clearance (1.1 and 0.8 ml/min/kg).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),[ml] / [kg·min],1.33,222585,DB00816,Orciprenaline
,6434219,clearance,"Propranolol had no significant effect on lorazepam t1/2 (13.2 and 12.7 hr) or clearance (1.33 and 1.36 ml/min/kg), nor on alprazolam t1/2 (15.9 and 18.5 hr) or clearance (1.1 and 0.8 ml/min/kg).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),[ml] / [kg·min],1.36,222586,DB00816,Orciprenaline
,6434219,t1/2,"Propranolol had no significant effect on lorazepam t1/2 (13.2 and 12.7 hr) or clearance (1.33 and 1.36 ml/min/kg), nor on alprazolam t1/2 (15.9 and 18.5 hr) or clearance (1.1 and 0.8 ml/min/kg).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),h,15.9,222587,DB00816,Orciprenaline
,6434219,t1/2,"Propranolol had no significant effect on lorazepam t1/2 (13.2 and 12.7 hr) or clearance (1.33 and 1.36 ml/min/kg), nor on alprazolam t1/2 (15.9 and 18.5 hr) or clearance (1.1 and 0.8 ml/min/kg).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),h,18.5,222588,DB00816,Orciprenaline
,6434219,clearance,"Propranolol had no significant effect on lorazepam t1/2 (13.2 and 12.7 hr) or clearance (1.33 and 1.36 ml/min/kg), nor on alprazolam t1/2 (15.9 and 18.5 hr) or clearance (1.1 and 0.8 ml/min/kg).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),[ml] / [kg·min],1.1,222589,DB00816,Orciprenaline
,6434219,clearance,"Propranolol had no significant effect on lorazepam t1/2 (13.2 and 12.7 hr) or clearance (1.33 and 1.36 ml/min/kg), nor on alprazolam t1/2 (15.9 and 18.5 hr) or clearance (1.1 and 0.8 ml/min/kg).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),[ml] / [kg·min],0.8,222590,DB00816,Orciprenaline
,18770048,time for 75% to be released (t(75)),The release pattern of drug from F16 containing 40 mg Kollidon SR divided in the core tablet (15 mg) and the rest in the compressed coat (25 mg) showed a typical zero order release kinetic that could extend drug release >10 h and reasonable time for 75% to be released (t(75)) (8.92 h).,Preparation and in-vivo pharmacokinetic study of a novel extended release compression coated tablets of fenoterol hydrobromide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18770048/),h,8.92,259061,DB00816,Orciprenaline
,18770048,MRT,When compared to immediate release Berotec tablet the MRT was significantly extended from 7.03 +/- 0.76 to 10.93 +/- 1.25 h (P < 0.001) and HVD(t 50%Cmax) was also significantly extended from 2.71 +/- 0.68 to 6.81 +/- 0.67 h with expected prevention of nocturnal asthma.,Preparation and in-vivo pharmacokinetic study of a novel extended release compression coated tablets of fenoterol hydrobromide. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18770048/),h,7.03,259062,DB00816,Orciprenaline
,18770048,MRT,When compared to immediate release Berotec tablet the MRT was significantly extended from 7.03 +/- 0.76 to 10.93 +/- 1.25 h (P < 0.001) and HVD(t 50%Cmax) was also significantly extended from 2.71 +/- 0.68 to 6.81 +/- 0.67 h with expected prevention of nocturnal asthma.,Preparation and in-vivo pharmacokinetic study of a novel extended release compression coated tablets of fenoterol hydrobromide. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18770048/),h,10.93,259063,DB00816,Orciprenaline
,18770048,t 50%Cmax),When compared to immediate release Berotec tablet the MRT was significantly extended from 7.03 +/- 0.76 to 10.93 +/- 1.25 h (P < 0.001) and HVD(t 50%Cmax) was also significantly extended from 2.71 +/- 0.68 to 6.81 +/- 0.67 h with expected prevention of nocturnal asthma.,Preparation and in-vivo pharmacokinetic study of a novel extended release compression coated tablets of fenoterol hydrobromide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18770048/),h,2.71,259064,DB00816,Orciprenaline
,18770048,t 50%Cmax),When compared to immediate release Berotec tablet the MRT was significantly extended from 7.03 +/- 0.76 to 10.93 +/- 1.25 h (P < 0.001) and HVD(t 50%Cmax) was also significantly extended from 2.71 +/- 0.68 to 6.81 +/- 0.67 h with expected prevention of nocturnal asthma.,Preparation and in-vivo pharmacokinetic study of a novel extended release compression coated tablets of fenoterol hydrobromide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18770048/),h,6.81,259065,DB00816,Orciprenaline
